RxDoctor Payments Data

Kusay Barakat, MD

Cardiovascular Disease · Frederick, MDNPI 1952306730

Payments from drug & device makers

$10,857in general payments, 2019–2025

Across 476 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Sanofi-aventis U.S. LLC$1K
  • Amgen$668
  • Amarin Pharma, Inc.$658
  • Novartis$633
  • Medtronic$617
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$3253%
  • Speaking & faculty fees$7006%
  • Food & beverage$9,83291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,857 in reported general payments places this provider in the 80th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$820,761
Medicare patients
1,730
Services billed
9,443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban680$882,351
XareltoRivaroxaban272$362,176
EntrestoSacubitril/Valsartan107$160,518
JardianceEmpagliflozin60$82,629
MultaqDronedarone Hcl36$69,771
Repatha SureclickEvolocumab45$64,812
FarxigaDapagliflozin Propanediol32$42,638
VascepaIcosapent Ethyl26$19,501
BrilintaTicagrelor16$16,707
Repatha SyringeEvolocumab11$15,504
Praluent PenAlirocumab18$15,441
Metoprolol Succinate697$14,147
Atorvastatin Calcium870$12,752
Rosuvastatin Calcium383$10,316
Ranolazine ErRanolazine48$8,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$322$882,351680 claims
Johnson & JohnsonXarelto$590$362,176272 claims
NovartisEntresto$633$160,518107 claims
Boehringer IngelheimJardiance$319$82,62960 claims
Sanofi-aventis U.S. LLCMultaq$1,016$69,77136 claims
AstraZenecaFarxiga, Brilinta$375$59,34448 claims
Esperion Therapeutics, Inc.Nexletol$517$7,84712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →